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Simple Summary: Pheochromocytomas/paragangliomas (PPGL) are rare tumors originating from
chromaffin tissues. Around 40% of pheochromocytomas/paragangliomas (PPGL) harbor germline
mutations, representing the highest heritability among human tumors. Unfortunately, there are no
available molecular markers for the metastatic potential of these tumors, and the prognosis of metastatic
forms is rather dismal. In this review, we present the potential relevance of non-coding RNA molecules
including microRNAs, long non-coding RNAs and circular RNAs in PPGL pathogenesis and diagnosis.
The pathomechanisms presented might also represent potential novel therapeutic targets.
Abstract: Around 40% of pheochromocytomas/paragangliomas (PPGL) harbor germline mutations,
representing the highest heritability among human tumors. All PPGL have metastatic potential, but
metastatic PPGL is overall rare. There is no available molecular marker for the metastatic potential of
these tumors, and the diagnosis of metastatic PPGL can only be established if metastases are found
at “extra-chromaffin” sites. In the era of precision medicine with individually targeted therapies and
advanced care of patients, the treatment options for metastatic pheochromocytoma/paraganglioma
are still limited. With this review we would like to nurture the idea of the quest for non-coding
ribonucleic acids as an area to be further investigated in tumor biology. Non-coding RNA molecules
encompassing microRNAs, long non-coding RNAs, and circular RNAs have been implicated in
the pathogenesis of various tumors, and were also proposed as valuable diagnostic, prognostic
factors, and even potential treatment targets. Given the fact that the pathogenesis of tumors includ-
ing pheochromocytomas/paragangliomas is linked to epigenetic dysregulation, it is reasonable to
conduct studies related to their epigenetic expression profiles and in this brief review we present
a synopsis of currently available findings on the relevance of these molecules in these tumors
highlighting their diagnostic potential.
Keywords: pheochromocytoma; paraganglioma; genetics; non-coding RNA; malignancy; biomarker;
treatment
1. Introduction
Non-coding RNA molecules encompassing microRNAs, long non-coding RNAs, and
circular RNAs have been implicated in the pathogenesis of various tumors, and were
also proposed as valuable diagnostic and prognostic factors, and even potential thera-
peutic targets. Given the fact that the pathogenesis of tumors including pheochromocy-
tomas/paragangliomas (PPGL) is partly linked to epigenetic dysregulation [1], it is reason-
able to investigate their epigenetic expression profiles.
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Pheochromocytomas are rare (incidence is approximately 0.8 per 100,000 people per
year) catecholamine-producing endocrine tumors, arising from neural-crest-derived chro-
maffin cells. They have a strong genetic background and originate either in the adrenal
medulla (80%) or in the sympathetic or parasympathetic paraganglia (20%), “extra-adrenal
pheochromocytomas” (paraganglioma) as formerly referred to in [2]. A considerable pro-
portion (40%) of pheocromocytoma/paraganglioma (PPGL) is diagnosed as manifestations
of hereditary tumor syndromes, including familial paraganglioma syndrome types 1–5
(mutations in genes coding for subunits and associated factors of succinate dehydrogenase
(SDH), e.g., SDHB, SDHC, SDHD, SDHA and SDHAF2 (collectively called SDHx), von
Hippel-Lindau syndrome (mutations of VHL tumor suppressor), multiple endocrine neo-
plasia type 2 (mutations of the RET protooncogene), neurofibromatosis type 1 (mutations
of NF1 tumor suppressor) and other germline mutations of various genes linked to major
pathogenic processes in PPGL pathogenesis (e.g., HIF2A, MAX, MDH2, FH, TMEM127,
KIF1B, PHD/EGLN1) [3–5]. At present, there are more than 12 genetic syndromes and 22
PPGL driver genes that contribute to PPGL formation [6,7]. This proportion of germline mu-
tations has the highest degree of heritability among human tumors [8]. Moreover, sporadic
PPGL were found to harbor somatic mutations in genes corresponding to their germline
counterparts [9].
The molecular etiology of PPGL is especially important to explore as PPGL display
various driver mutations with serious impact on diagnosis, prognosis and therapy as
well. As a familial disease, early genetic diagnosis can not only facilitate the treatment of
the proband, but is also an important step to detect potentially mutation carriers in the
family [10]. Another reason for genetic testing is the well-known causative link between
some driver mutations and their metastatic potential [8]. The rate of metastatic forms of
catecholamine-secreting tumors is rather variable in different studies ranging between
5–26%. On the other side up to 50% of patients with metastatic PPGL have specific germline
mutations [11–13]. The risk of metastasis is particularly high in individuals harboring
germline SDHB mutations [12]. PPGL susceptibility can be associated with mutations
either in tumor suppressor genes (e.g., VHL, NF1, SDHB) or in proto-oncogenes (e.g., RET,
HRAS) [7].
In order to further specify PPGL types and their tumor behavior, according to another
recent paper, PPGL can further be classified into four molecular subtypes [14] (Figure 1).
These groups include Wnt-altered, kinase signaling, pseudohypoxia, and cortical admixture
subtypes with different molecular features and also clinical behavior. For example, the
Wnt-altered subtype seems to be specific for sporadic PPGL as no germline mutations were
observed within these tumors. The pseudohypoxia type generally had no epinephrine or
metanephrine secretion, and also showed overexpression of the previously described tumor
hypoxia marker microRNA-210 (miR-210) [15]. The cortical admixture type was found to
be correlated with MAX (MYC associated factor X) mutations, which is also included as
one of the susceptibility genes for hereditary PPGL [16]. Finally, kinase signaling exhibited
the highest expression of PNMT (phenylethanolamine N-methyltransferase), an enzyme
known to convert norepinephrine to epinephrine and according to that, was found mainly
in pheochromocytomas.
From the clinical point of view, primary symptoms of excessive catecholamine se-
cretion are episodic headache, sweating, and tachycardia (palpitations), also called the
“classic triad” [17,18]. Either sustained or paroxysmal hypertension and even unexplained
orthostatic hypotension are also characteristic features of PPGL. Other non-specific signs
related to catecholamine-excess are anxiety, panic attacks, tremor, pallor, frequent urination,
constipation, vision disturbances, hyperglycemia, and severe cardiovascular complications
including stroke, aortic dissection, and stress-induced (takotsubo) cardiomyopathy [19].
In the so-called “pheochromocytoma crisis” patients suffer from hyperthermia, mental
status change, and multisystem dysfunction, hence they require immediate medical at-
tention [20]. Signs related to the general properties of a tumor are pain—depending on
tumor location—weight loss, hematuria, and rarely erythrocytosis due to overproduction
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of erythropoietin [21]. Ever-increasingly, PPGL often appear with no associated symptoms
as an incidental finding on imaging performed for other purposes (approximately 5–8%
of adrenal incidentalomas), and also due to genetic screening in the context of familial
disease [5].




Figure 1. Clinically relevant functions of the four molecular pathways contributing to pheochromocytomas/paragangli-
omas (PPGL). (A) Wnt-Hedgehog overexpressed subtype included mainly adrenal sporadic pheochromocytomas and 
high chromogranin A levels. MAML3 and CSDE1 are independently important driver mutations leading to Wnt-Hedge-
hog activation. (B) Kinase signaling pathway is correlated to pheochromocytomas of adrenergic phenotype due to over-
expression of PNMT, comprising somatic- and germline mutations and chromosomal deletions, as well. (C): Pseudohy-
poxia subtype, in addition to somatic- and germline mutations and chromosomal amplification, also exhibited overex-
pression of miR-210. (D) Overexpression of CYP11B1, CYP21A2, and STAR adrenal cortex markers was characteristic to 
cortical admixture subtype, along with MAX mutation in PPGL. g. mutation: germline mutation; s. mutation: somatic 
mutation; s.g. mutation: somatic and germline mutation; WNT4: wingless-related integration site 4; DVL3: dishevelled 3; 
CHGA: encodes chromogranin A (CgA); NET: neuroendocrine tumor; MAML3: mastermind-like transcriptional coactiva-
tor 3; CSDE1: cold shock domain containing E1; RAS: rat entry sarcoma; MAPK: mitogen-activated protein kinase; PNMT: 
phenylethanolamine N-methyltransferase; NE: norepineprhrine; E: epinephrine; RET: rearranged during transfection; 
TMEM127: transmembrane protein 127; HRAS: Harvey rat sarcoma viral oncogene homolog; NF1: neurofibromatosis 1; 
BRAF: v-raf murine sarcoma viral oncogene homolog B1; NGFR: nerve growth factor receptor; SDH: succinate dehydro-
genase; VHL: Von-Hippel Lindau; EPAS1: endothelial PAS domain 1; CYP11B1: cytochrome P450 family 11 subfamily B 
member 1; CYP21A2: cytochrome P450 family 21 subfamily A member 2; STAR: steroid acute regulatory protein; MAX: 
myc associated factor X. 
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plasma metanephrine [22–24]. The general neuroendocrine tumor marker chromogranin 
Figure 1. Clinically relevant functions of the four molecular pathways contributing to pheochromocytomas/paragangliomas
(PPGL). (A) Wnt-Hedgehog overexpressed subtype in luded mainl adrenal sporadic pheochromocytomas and hi h
chromogranin A levels. MAML3 and CSDE1 are independe t y importa t driver mutations leading to Wnt-Hedgehog
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of PNMT, comprising somatic- and germline mutations and chromosomal deletions, as well. (C): Pseudohypoxia subtype,
in addition to somatic- and germline mutations and chromosomal amplification, also exhibited overexpression of miR-210.
(D) Overexpression of CYP11B1, CYP21A2, and STAR adrenal cortex markers was characteristic to cortical admixture
subtype, along with MAX mutation in PPGL. g. mutation: germline mutation; s. mutation: somatic mutation; s.g.
mutation: somatic and germline mutation; WNT4: wingless-related integration site 4; DVL3: dishevelled 3; CHGA: encodes
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Diagnosis of PPGL is based on a thorough clinical examination and medical history
followed by biochemical tests, diagnostic imaging, and genetic testing. Biochemical tests
include measuring 24 h urinary fractionated metanephrines and catecholamines or plasma
metanephrine [22–24]. The general neuroendocrine tumor marker chromogranin A (CgA)
is also useful. However, CgA is not specific for PPGL, but as its serum levels correlate with
tumor burden, it is applicable for monitoring PPGL patients [25]. Patients with positive
biochemical test results need to proceed on radiological evaluation, such as 123I-MIBG
scan (meta-iodobenzylguanidine), MRI (magnetic resonance imaging), CT (co puted
tomography), 18FDG PET-CT (fluorodeoxyglucose positron emission tomography), or
68Ga-DOTATATE-PET (dodecanetetraacetic tyrosine-3-octreotate) [26].
Beside the clinical evaluation, at present, there are no reliable histomorphological
feat res to distinguish between benign and metastatic PPGL, however Pheochromocytoma
of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adre al Pheochro-
mocyt a nd Paraganglioma (GAPP) have been evaluated in a recent meta-an lysis as
promising to ls with goo negative predictive value [27]. The rec t WHO classifica-
tion om tte the t rms benign and malignant pheochromocytoma, and defined metastatic
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PPGL as a tumor with metastases at “extra-chromaffin” sites [28]. Patients with metastatic
PPGL have poor prognosis with an estimated 44% overall survival (OS) at 5 years due to
limited treatment options [29]. Whereas some patients present with synchronous metas-
tases, metastases occur in several patients after the removal of the primary tumor, i.e.,
in a metachronous fashion. Long-term monitoring in all patients is warranted, even in
those patients seemingly cured from the disease, which is obviously a life-long burden
for such patients [30]. Metastasis in PPGL can occur as long as 53 years after surgery [31].
Unfortunately, despite intensive efforts, there are no reliable molecular markers of the
metastatic potential of PPGL either. Altogether, according to the current WHO classifica-
tion, all PPGL should be regarded as potentially malignant/metastatic, and followed up,
but only a minority of PPGL will actually metastasize [32,33].
Currently, the primary treatment of PPGL is surgical resection, although removal of
the tumor does not always lead to the cure of PPGL or to normotension [30]. However, it
is possible that successful surgical treatment can not only be curative, but can also lead
to normotension, normalization of blood pressure variability, and even normalization of
urinary metanephrines [34]. Undiagnosed or not properly treated PPGL has high morbidity
and mortality rate mainly due to cardiovascular complications. Other complications can
also be life-threatening, such as drug interactions, hypertensive crises due to diagnostic-
or therapeutic manipulations—owing to the sympathetic activation, and also malignancy
or associated neoplasms [35]. For metastatic PPGL, there is no curative treatment, and
currently available systemic chemotherapeutic approaches (e.g., CVD—cyclophosphamide-
vincristin-dacarbazin chemotherapy) have limited efficacy [36]. Novel treatment options
including VEGF (vascular endothelial growth factor) and tyrosine kinase inhibitors (e.g., ax-
itinib, dovitinib, lenvatinib, sunitinib) exist for patients with SDHA, SDHB, SDHD, RET,
VHL, and FH mutations in renal cell carcinoma and PPGL; furthermore, immunotherapies
targeting PD-L1 (programmed death-ligand 1) checkpoint protein (e.g., pembrolizumab, ip-
ilimumab, nivolumab) are currently under clinical investigation [37–41]. Poly ADP-ribose
polymerase (PARP) inhibitors (e.g., olaparib) represent another perspective in patients
harboring SDHx mutations due to elevated levels of succinate and NAD+ inhibiting ho-
mologous recombination-based DNA repair mechanism which is known to be corrected by
PARP, thus keeping aberrant cells alive [42]. Furthermore, there are two kinase signaling
pathways (PI3K-Akt-mTOR and Ras-Raf-Erk) affected by mutations of RET, MAX, NF1,
and TMEM127, which can be inhibited by kinase signaling inhibitors (e.g., the mTOR
inhibitor everolimus) [43]. Isotope therapies such as 131I-MIBG or somatostatin-analogue-
based radiotherapies are also effective [32]. For more details on the current trials in PPGL,
the reader is referred to the article by Ilanchezian et al., 2020 [44].
Given the difficulties in PPGL diagnosis, especially the lack of markers of malignancy,
non-coding RNA (ncRNA) molecules are gaining increasing attention, as they have been
proven to be useful in other neoplasms, as well [45].
2. Classification of ncRNA
Recent progress in the field of molecular biology has revealed that only 1–2% of the
transcripts encode for protein (mRNA: messenger RNA), while 90% of the genomic DNA is
transcribed. Most of these are transcribed as non-coding RNA; nevertheless, ncRNAs still
bear major biological functions [46]. They are epigenetic modulators of gene expression by
chromatin remodeling, transcriptional regulation, and posttranscriptional modification.
ncRNAs can further be classified as structural ncRNAs, like ribosomal RNAs (rRNAs),
transfer RNAs (tRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs),
and as regulatory ncRNAs, including microRNAs (miRNAs, miRs), PiWi-interacting RNAs
(piRNAs), small interfering RNAs (siRNAs), long non-coding RNAs (lncRNA), enhancer
RNAs (eRNAs), and circular RNAs (circRNAs) [47,48]. These molecules span across the
landscape of cancer biology. Tumors are inherently genetic diseases that derange cellular
homeostasis and work towards cellular growth. Non-coding RNA molecules have been
shown to be implicated in the pathogenesis of tumors [49,50].
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Long non-coding RNAs (usually from 200 to thousands of nucleotides long) are
evolutionarily conserved and highly specific to cell/tissue types [51]. lncRNAs have been
recently shown to be implicated in important regulatory mechanisms, as it was a long
standing view not only about lncRNAs, but also about circRNAs to add no further values
than being byproducts of their cognate mRNAs [52]. Surprisingly, the number of lncRNA
coding genes even exceeds the number of protein coding genes, but the function of the
bulk of them remains to be identified. Cellular mechanisms of lncRNAs relate to their
localization within the cell. For example, nuclear transcripts control chromatin functions,
transcription, and RNA processing; on the other hand, cytoplasmic lncRNAs have an effect
on mRNA stability, translation, and cellular signaling (Figure 2). In different circumstances,
functions of lncRNAs not only involve intracellular mechanisms, but may also act on an
intercellular level, e.g., contribute to development of the tumor microenvironment and
other hallmarks of cancer [53].
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The relevance of circular RNAs (covalently bonded 3′ and 5′ ends) in biological
and pathological processes has been shown only recently [54]. These peculiarly stable,
evolutionarily conserved molecules play major roles mainly in the post-transcriptional
regulation of gene expression e.g., by acting upon transcriptional, translational machinery
or by sponging microRNAs (Figure 2). Furthermore, altered expression of circRNAs has
been described in various tumors; for example, circHIPK functions as a miRNA sponge
in colorectal, hepatocellular, kidney, prostate, breast, gastric, and bladder cancer, while
hsa_circ_0004277 seems to be a potential biomarker and therapeutic target in acute myel-
ogenous leukemia [55,56]. CircRNAs are formed from the intron-containing pre-mRNA in
a process called “backsplicing”, but they are expressed in a different manner to their linear
counterparts. Differential expression of circRNAs is explicable via, e.g., different structures
of introns (reverse complementary repeat sequences) [57]. Furthermore, one of the most
interesting aspect of circRNAs is their potential as biomarkers, as they exhibit high stability
compared to other linear RNAs and they show cell-type-specific expression profiles [58,59].
There are four different types of circular RNAs: i. 2′-5′ intronic circRNA (ciRNA) localized
in the nucleus, ii. 3′-5′ exon-intron circRNA (EIciRNA) also with nuclear localization, iii.
intergenic circRNA located in the cytoplasm, and the most abundant, iv. exonic circRNA
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(ecircRNA), also localized in the cytoplasm [60,61]. Circular RNAs exert their biological
potential via two mechanisms: via backsplicing and subsequent competition with their
linear counterpart from the host gene and via trans-regulatory effect of the circRNA end
product. Their effect on gene expression can further be divided into six mechanisms: i.
sequestration of miRNA, so-called miRNA “sponges”; ii. stimulation of initiation and
elongation of transcription by acting upon RNA polymerase II; iii. down-regulation of
cognate mRNAs by attenuation of linear splicing; iv. through protein binding they are
able to inhibit translational activity; v. a portion of them is protein coding circRNA; vi.
circRNAs can alter enzymatic reactions by forming ternary complexes [62,63].
MicroRNAs (miR, miRNA) have been proposed to have a major impact on biolog-
ical function of tumors and are of great interest as candidates of liquid biopsy. Mature
miRs are single-stranded, short RNA molecules comprising 19–25 nucleotides, that are
also evolutionarily conserved and encoded by proper miRNA genes [64]. They have a
role in the regulation of 30–60% of human genes in epigenetic, posttranscriptional mod-
ification, without altering the very sequence of DNA. MicroRNAs are shown to behave
similarly to transcription factors (TF). While TFs exert their activating or silencing effect
by binding to a specific region of the promoter in the nucleus, miRNAs bind to the 3′
UTR (untranslated region) of their mRNA target, hence degrading them or blocking their
translation in the cytoplasm; however, they can also act in the nucleus (Figure 2) [65,66].
Today, we see an abundance of the biological functions of miRs. Their pleiotropic effects
include the regulation of cell cycle and differentiation, cell proliferation, hormone secretion,
apoptosis and are also implicated in the regulation of hemopoiesis, immune functioning,
and ontogenesis. Several pathogenic processes including tumorigenesis, autoimmune
disorders, and vascular diseases among others can be found to be associated with altered
miRNA expression [67]. Another important aspect of miRs is their cell- and tissue-specific
expression. Cell-specificity means that the expression of miR is different in various tissues,
moreover a certain miR can act differently, either as a silencer or rarely an activator in
different tissues [65]. In line with this, a miR can be a tumor suppressor in one tissue and
an oncogene in another making regulation via miR rather complex and local. Thanks to
their abundance and exceptionally high stability, miR expression profiles can be studied in
easily accessible archived formalin-fixed paraffin-embedded tissue samples and—being
secreted—even in bodily fluids [68,69]. These aforementioned features make microRNAs
some of the most studied molecules in the field of minimally invasive diagnostics of neo-
plastic and non-neoplastic diseases—especially true with “hard-to-diagnose” entities like
adrenal tumors or thyroid tumors [70].
3. Non-Coding RNAs in PPGL
3.1. CircRNAs in PPGL
To date, only one study has investigated the expression pattern of circular RNAs in
PPGL, suggesting its role in histone methylation [71]. The authors performed RNA se-
quencing on circRNA transcripts of tumor tissue compared to adjacent normal tissue from
PPGL patients. In the discovery cohort, seven patients were randomly assigned in order to
perform transcriptome analysis, which revealed 3927 mRNAs, 283 miRNAs, and 367 cir-
cRNAs to be differentially expressed. The top 11 differentially expressed circRNAs have
been validated by real-time quantitative PCR (RT-qPCR) on 33 pairs of PPGL tumor tissues
and adjacent normal tissues from snap-frozen samples. Out of 367 differentially expressed
circRNAs 112 were shown to be down-regulated and 255 were up-regulated. The top three
overexpressed histone methylation-related circRNAs (hsa_circ_0000567, hsa_circ_0002897,
and hsa_circ_0004473) related to histone methylation were identified and validated as well
as their miRNA targets (Table 1). These three circRNAs were also found to be differentially
expressed in the peripheral blood from 16 PPGL patients and 16 healthy individuals. By
bioinformatical analysis, hsa_circ_0000567 was predicted to bind hsa-miR-96-3p, which is
involved in the regulation of histone methylation [71]. Furthermore, a coding-non-coding
gene co-expression network (CNC) was established by mapping of circRNA-miRNA-
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mRNA transcripts involving known PPGL susceptibility genes. It has been proposed that
these circRNAs related to histone methylation function as miRNA sponges.
Table 1. Functions of ncRNAs with altered expression in PPGL.
ncRNA Method and Sample(Number of Patients) Expression Alteration and Suggested Role Ref.
hsa-circ-0000567
RNA-seq
(M = 7, N = 7)/
RT-qPCR
(M = 33, N = 33)
related to histone methylation;
predicted to bind hsa-miR-96-3p [71]
hsa-circ-0002897
RNA-seq
(M = 7, N = 7)/
RT-qPCR
(M = 33, N = 33)
related to histone methylation [71]
hsa-circ-0004473
RNA-seq
(M = 7, N = 7)/
RT-qPCR
(M = 33, N = 33)
related to histone methylation [71]
hsa-miR-15a
Microarray
(M = 12, B = 12, N = 5)/
RT-qPCR
(B = 10, M = 10)
tumor suppressor;
promotes cell death via downregulation of CCND1;




(M = 12, B = 12, N = 5)/
RT-qPCR
(B = 10, M = 10)
tumor suppressor;
promotes cell death via downregulation of CCND1;
underexpressed in metastatic pheochromocytoma
[72]
hsa-miR-21-3p
Discovery cohort: 443 metastatic vs.
non-metastatic samples;
Validation cohort: 49 non-metastatic
and 8 non-metastatic vs. metastatic
regulates TSC2/mTOR axis;
association in expression with sensitivity to rapamycin [73]
hsa-miR-96-3p
RNA-seq
(M = 7, N = 7)/
RT-qPCR
(M = 33, N = 33)
regulates histone methylation;
predicted to bind hsa-circ-0000567 [64]
hsa-miR-101
Microarray
(M = 8, B = 42, N = 21)/
RT-qPCR
(M = 25, B = 36, N = 21)
overexpression in SDHB mutant;
overexpression in metastatic pheochromocytoma [74]
hsa-miR-133b
Microarray
(M = 5, B = 58, N = 6)/
RT-qPCR
(M/B = 28, N = 2)
overexpression in VHL type PPGLs [75]
hsa-miR-137
Microarray
(M = 5, B = 58, N = 6)/
RT-qPCR
(M/B = 28, N = 2)
overexpression in PPGL;






overexpression in VHL pheochromocytoma [68]
hsa-miR-183
Microarray
(M = 8, B = 42, N = 21)/
RT-qPCR
(M = 25, B = 36, N = 21)
overexpression in SDHB mutant;
overexpression in metastatic pheochromocytoma [74]
hsa-miR-193b RNA-seq(B/M = 183, N = 3)
underexpression in PPGL;
mediates TGFBR3 expression through BSN-AS2 competition [76]
hsa-miR-195 RNA-seq(B/M = 183, N = 3)
underexpression in PPGL;
mediates TGFBR3 expression through BSN-AS2 competition [76]
hsa-miR-210 RT-qPCR(B/M = 39)
overexpression in pseudohypoxia subtype;
tumor hypoxia marker;
associated with SDHx or VHL mutations
[15,77,78]
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Table 1. Cont.
ncRNA Method and Sample(Number of Patients) Expression Alteration and Suggested Role Ref.
hsa-miR-375 RNA-seq(B/M = 183, N = 3) overexpression is PPGL [76]
hsa-miR-382
Microarray
(M = 5, B = 58, N = 6)/
RT-qPCR
(M/B = 28, N = 2)
overexpression in tumors with VHL, SDHB, SDHD, RET mutations;
targeting SOD2, C-MYC [75]
hsa-miR-483-5p
Microarray
(M = 12, B = 12, N = 5)/
RT-qPCR
(B = 10, M = 10)
overexpression in metastatic PPGL;
underexpression in SDHB among metastatic PPGL;
worse disease-free survival in metastatic PPGL;




(M = 5, B = 58, N = 6)/
RT-qPCR
(M/B = 28, N = 2)
overexpression in RET PPGL [75]
hsa-miR-497 RNA-seq(B/M = 183, N = 3)
underexpression in PPGL;
mediates TGFBR3 expression through BSN-AS2 competition [76]
























overexpression in sporadic recurrent PPGL [68]
lncRNA BSN-AS2 RNA-seq(B/M = 183, N = 3)
negative association with OS;
mediate TGFBR3 expression through miR-193b, miR-195,
miR-497 competition
[76]
lncRNA C9orf147 RNA-seq(B/M = 183, N = 3) positive association with OS [76]
B—benign; M—metastatic; N—normal/control; OS—overall survival.
Limitations of this study include the small number of patients included and that the
control samples were derived from normal tissues adjacent to the tumor, instead of from
individuals adrenalectomized for other (non-PPGL-related) causes. Epigenetic alterations
can precede tumor formation (hence the prognostic value) and play major role in cell-to-cell
communication (hence the therapeutic value) and by analyzing differential expression
profiles, protein-protein interactions, gene set enrichment, dimensionality reduction, and
tissue composition, it was elucidated that normal tissues adjacent to the tumor represent a
unique in-between state concerning the molecular landscape [80]. Pan-cancer proinflam-
matory reaction in the adjacent endothelium was also suggested to bias the outcome of the
normal tissue adjacent to the tumor as control tissue. Moreover, in this study, pathway anal-
yses were also restricted only to bioinformatical predictions and the physical interaction
between hsa_circ_0000567 and hsa-miR-96-3p has not been confirmed, either.
3.2. Long Non-Coding RNAs in PPGL
It is important not only to detect the expression profiles of non-coding RNAs, but also
to have an understanding of their mechanistic interaction with other regulatory molecules.
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For example, some lncRNAs have binding sites with microRNAs, thus sequestering them,
thereby increasing the expression of their target genes.
In a competing endogenous RNAs (ceRNA) bioinformatics study, the expression of
mRNAs, miRNAs, and lncRNAs in PPGL related to non-tumorous tissues were analyzed
in datasets downloaded from the Cancer Genome Atlas (TCGA) [76]. To design a ceRNA
study, it is a basic principle that the more binding sites the lncRNA have, the stronger
they can down-regulate miRNA, thus inhibiting mRNA degradation. The authors observed
554 lncRNAs, 1775 mRNAs, and 40 miRNAs to be differentially expressed, from which
23 lncRNAs, 22 mRNAs, and 6 miRNAs were selected to build the ceRNA network. Twenty-
three lncRNAs were identified to be differentially expressed in PPGL, and among them two
were related to overall survival, i.e., lncRNA BSN-AS2 and C9orf147, without having been
described previously as related to other diseases. LncRNA BSN-AS2 and C9orf147 are future
candidates to investigate their roles in tumorigenesis as their overexpression was associated
with poor prognosis; moreover, the underexpression of C9orf147 was associated with good
prognosis (Table 1). Up-regulation of BSN-AS2 has been observed in 183 pheochromocytoma
patients related to a very low number (3) of control samples. As reported by the study,
BSN-AS2 might exert its impact on prognosis through altering receptor-type tyrosine-
protein phosphatase eta (PTPRJ) mRNA expression by interacting with miR-195 based on
bioinformatical predictions. PTPRJ underexpression was found to be correlated with good
prognosis. On the other hand, BSN-AS2 competes with miR-193b, miR-195 and miR-497,
thereby modulating TGFBR3 mRNA, which was positively associated with OS. Interestingly
enough, TGFBR3 mRNA levels were found to be underexpressed in pheochromocytoma
patients, therefore, we are still in need of explanation of divergent expression levels between
TGFBR3 mRNA and BSN-AS2 lncRNA. The findings of this bioinformatics study also need
to be validated experimentally.
A recently published study about the transcriptome analysis of lncRNAs in PPGL
revealed lncRNA phenotypes that can distinguish PPGL subtypes [81]. In the SDHx sub-
type, a putative lncRNA BC063866 was found to be able to distinguish between metastatic
tumors and tumors that remain indolent. lncRNA BC063866 was found to be related to
some of the genes involved in metastatic signature of various tumors such as CDH19,
ERBB3, PLP1, and SOX10. Interestingly, these genes are also involved in neural crest and
glial development [82]. Furthermore, lncRNA BC063866 was found to be an independent
risk factor for poor outcome in SDHx mutants, although this marker should be replicated
in large prospective cohorts, as well.
Additionally, in a more recent ceRNA bioinformatics study, the previously described
miR-195-5p and miR-34a-5p were predicted to be involved in the following two lncRNA–
miRNA–mRNA axes: AP001486.2/hsa-miR-195-5p/RCAN3 and AP006333.2/hsa-miR-34a-
5p/PTPRJ respectively, functioning as tumor suppressors [83]. Higher expression levels of
RCAN3 (regulator of calcineurin 3) and PTPRJ in PPGL compared with normal adjacent
tissue were experimentally validated by immunohistochemistry analysis. Matching with
normal adjacent tissue might bias the results, as it was outlined before. The ceRNA study
also revealed RCAN3 as a good prognostic marker. In contrast to the previous study [76],
this bioinformatical approach revealed underexpressed PTPRJ to be related to unfavorable
prognosis. The controversial results concerning the relevance of PTPRJ highlight the limita-
tions of bioinformatical analyses and the need for focused translational studies to establish
the marker potential of a given coding or non-coding RNA molecule. PTPRJ might be in-
volved in malignancies at different levels acting both as a tumor suppressor, but also in the
regulation of antitumoral T-cell activity [84,85]. In a similar manner, RCAN3 is implicated
in the calcineurin–nuclear factor of activated T cells (NFAT) pathway-mediated immune
response and also acts as a tumor suppressor [86]. It is also noteworthy that miR-483-5p,
miR-195, and miR-34a were shown to be differentially expressed in adrenocortical cancer,
as well [79,87].
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3.3. MicroRNA in PPGL
According to one of the first studies from our research group on the miRNA expression
profiles in FFPE samples of PPGL of various genetic backgrounds, miR-139-3p, miR-541
and miR-765 in VHL showed significantly higher expression compared to sporadic be-
nign pheochromocytomas [68]. Altered expression of miR-139-3p has been demonstrated
in various types of cancer [88–90]. miR-541 has been shown to be upregulated in VHL
compared with sporadic recurring pheochromocytomas (Table 1). Another finding has been
the overexpression of miR-885-5p in MEN2-related pheochromocytoma compared with
VHL- NF1-, sporadic recurring, and sporadic benign pheochromocytomas. Upregulated
expression of miR-1225-3p has been found in sporadic recurrent pheochromocytomas in
comparison to benign pheochromocytomas that raised its potential as a marker of PPGL
recurrence. By using a bioinformatics pathway analysis approach, we raised the relevance
of Notch-signaling in pheochromocytoma recurrence, and there are in vitro data showing
the anti-proliferative potential of Notch-modulation in pheochromocytoma [91].
The previously detailed ceRNA network study in pheochromocytoma revealed the
up-regulation of miR-137 and miR-375 and down-regulation of miR-193b, miR-195, miR-497,
and miR-508 [76].
The aforementioned recent ceRNA study also shed light on miR-148b-3p and miR-338-
3p in respect of favorable prognosis and overall survival in PPGL [83].
Studies aimed at understanding miR expression pattern changes between benign
and metastatic PPGL are pivotal in order to be able to differentiate between these two
entities. Whole-genome microarray profiling revealed eight miRNAs to be differentially ex-
pressed [74]. In this study, “malignancy” was established when there was clinical evidence
of tumor from “extra-chromaffin” sites corresponding to the current WHO definition of
metastatic PPGL, but also when there was extensive local invasion. Significantly altered
expression of miR-101, miR-183, and miR-483-5p was revealed in metastatic pheochromocy-
toma tissues versus benign ones and validated by RT-qPCR. Among them, miR-101 and
miR-183 significantly differed in SDHB mutant vs. wild type samples and interestingly, miR-
483-5p had significantly lower expression in SDHB mutant malignant pheochromocytoma
compared to all other malignant pheochromocytomas. Furthermore, miR-101, miR-183, and
miR-483-5p were measurable from serum samples, as well. In practice, this might raise the
possibility that a patient without SDHB mutation might be screened for miR expression
profile changes to assess the risk of malignancy. In another study investigating snap-frozen
samples, significantly higher expression of miR-483-5p in metastatic PPGL was found, as
well, validated by RT-qPCR [72]. The definition of metastatic disease corresponded to the
WHO definition in this study, i.e., only tumors with metastases at “extra-chromaffin” sites
were considered metastatic. On the other hand, lower expression of the general tumor
suppressor miRNAs miR-15a and miR-16 were revealed in metastatic versus benign tumors.
miR-15 and miR-16 were raised as potential therapeutic targets, as their restoration in
expression promoted cell death, partly through the down-regulation of CCND1 (Cyclin D1)
in metastatic rat pheochromocytoma cells [72]. Up-regulation of miR-483-5p in metastatic
tumors corresponded to the amplification of IGF2 (insulin-like growth factor 2) mRNA
due to their co-expression from the same locus [72]. IGF2 protein and mRNA were shown
to be significantly increased in metastatic PPGL, which is consistent with other studies
investigating the relationship between IGF2, miR-483-5p, and adrenocortical carcinoma,
where miR-483-5p is also overexpressed in comparison to benign adrenocortical adeno-
mas [70,79]. Moreover, miR-483-5p is a marker of worse disease-free survival in metastatic
pheochromocytoma [72].
As mentioned before, miR-210 (a general hypoxamiR [92]) is a key molecule in
pseudohypoxia-type PPGL functioning as a master regulator [77]. When PPGL was com-
pared with normal adrenal medullary tissues, overexpressed miR-210 was significantly
associated with SDHx or VHL mutant genotypes known to exhibit the pseudohypoxia
phenotype [78].
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The aforementioned miR-96 and miR-183 were described to contribute to the differ-
entiation block of cells of SDHB mutated tumors [93]. An integrative study of expression
signatures of PPGL revealed that miR-382 targeting SOD2 (superoxide dismutase 2) and
C-MYC was up-regulated in tumors of most genetic backgrounds (VHL, SDHB, SDHD,
RET) except in MAX mutants [75]. Up-regulation of miR-137 was also observed in most
genetic backgrounds (VHL, SDHB, SDHD, RET) except in MAX. miR-137 possibly down-
regulates RUNX2, KDM5B (histone H3 Lys4 demethylase) and interferes with IDH1–EGLN
pathway, thus regulating neuronal gene activity as it has been previously reported [94].
miR-885-5p (interestingly a tumor suppressor) and miR-488 were specific to MEN2-related
PPGLs. miR-133b was related to VHL-type PPGLs. Robust upregulation was identified
with miR-96 especially in SDHB mutants [75].
In neuronal pheochromocytoma 12 cells (PC-12) miR-18a is involved in hypoxic re-
sponses through down-regulation of lncRNA urothelial carcinoma associated 1 (UCA1),
sex determining region Y-box 6 (SOX6), and hypoxia inducible factor 1 subunit α (HIF-
1α) [95]. However, the regulatory functions of miR-18a on HIF-1α have only been described
previously in lung cancer stem-like cells, choroidal endothelial cells, and in a breast cancer
xenograft model [96–98]. Given the tissue-specific nature of miRNA expression and action,
the interaction between miR-18a and HIF-1α in PPGL should be investigated in pheochro-
mocytoma cells. Under hypoxic conditions, UCA1 is upregulated, making cells more prone
to hypoxic injuries through the putative down-regulation of miR-18a. Down-regulation of
UCA1 is associated with the attenuation of hypoxic injuries. Furthermore, UCA1 directly
targets and down-regulates miR-18a and vice versa, and the up-regulation of miR-18a
alleviates hypoxic injury through downregulation of UCA1. Similar to UCA1, SOX6 also
acts as a provoking factor in hypoxic injuries and inhibition of SOX6 leads to an ease of
hypoxic injury (Figure 3).
MiR profiling also holds therapy-modifying potential in precision medicine. A recent
study revealed a new regulatory axis of miR-21-3p/TSC2/mTOR signaling pathway as a
future target for treatment, as miR-21-3p showed significant association with sensitivity to
rapamycin, thus, miR-21-3p could be a marker for mTOR inhibitor therapy (Figure 3) [73].
This study not only shed light on miR profiling as a tool in risk stratification in PPGL, but
also gives us a predictive biomarker accessible via liquid biopsy to investigate in a larger
cohort in the future.
It is quite intriguing that some microRNAs seem to be differentially expressed between
both benign and metastatic PPGL and benign and malignant adrenocortical tumors. These
include miR-483-5p, miR-195, and miR-34a [72,74,76,79,83,87]. As the adrenal cortex is of
mesodermic origin, whereas the adrenal medulla is of ectodermic origin, these common
changes in microRNA expression might even suggest some common adrenal-specific
features in tumorigenesis. Confirmation in larger cohorts is warranted.
Based on these significant differences in expression profiles, miR, lncRNA, and cir-
cRNA profile analysis are still one of the chief candidates for an adjunct diagnostic marker
for “hard-to-diagnose” tumors.
3.4. ncRNAs as Therapeutic Targets in PPGL
Currently, there are no clinical studies evaluating ncRNAs as therapeutic targets in
PPGL. Since treatment options for metastatic PPGL are rather limited, novel molecular
targets are intensively sought for. We can only hypothesize on the relevance of ncRNAs
in the treatment of PPGL from specific observations. Some of the ncRNA detailed above
might represent potential treatment targets or exploited as markers of therapy-modifying
potential. For example, miR-21-3p was shown to be correlated with rapamycin sensitivity,
thus, miR-21-3p could be a marker for mTOR inhibitor therapy in PPGL (Figure 3) [73].
Detailed preclinical molecular investigations will be necessary to define the ncRNA that
could be exploited as treatment targets (e.g., restoration of underexpressed “tumor suppres-
sor” ncRNA expression or targeting overexpressed oncogenic ncRNA by small interfering
RNA), but there would be quite a long way ahead before the clinical application of any
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treatments targeting these pathways given the numerous difficulties in such treatment
strategies (e.g., problems of administration, question of the vector, off-site effects, etc.) [99].




Figure 3. miRNA interactions in pheochromocytoma: Transmembrane tyrosine kinase receptor activation is the first step 
in the mTOR signaling pathway; thunderbolt represents activation of mTOR pathway in pheochromocytoma; P indicates 
phosphorylation sites; blunt-head lines indicate inhibition; faded arrows indicate downstream activation; solid arrows 
indicate direct activation; right-angle arrow indicates gene expression. Abbreviations: BSN-AS2: long non-coding RNA 
BSN-AS2; OS: overall survival; PTPRJ: receptor-type tyrosine-protein phosphatase eta; TGFBR3: transforming growth fac-
tor beta receptor 3; PI3K: phosphoinositide 3-kinase; PTEN: phosphatase and tensin homolog; PDK1: phosphoinositide-
dependent kinase 1; AKT1: a serine/threonine protein kinase; TSC1/2: tuberous sclerosis complex subunit 1; Rheb: Ras 
homolog enriched in brain; GTP: guanosine triphosphate; GDP: guanosine diphosphate; mTROC1: mammalian target of 
rapamycin complex 1; rapamycin: mTOR inhibitor; UCA1: long non-coding RNA urothelial cancer associated 1; SOX6: 
SRY (sex determining region Y)-box 6; HIF-1 α/β: hypoxia inducible factor 1 subunit α/β; HRE: hypoxia response element; 
PC-12: pheochromocytoma 12 cell line, OS: overall survival. Note that miR-18 mediated down-regulation of HIF-1α has 
only been established in lung cancer stem-like cells, choroidal endothelial cells, and in breast cancer xenograft model and 
not yet in pheochromocytoma cells. 
It is quite intriguing that some microRNAs seem to be differentially expressed be-
tween both benign and metastatic PPGL and benign and malignant adrenocortical tu-
mors. These include miR-483-5p, miR-195, and miR-34a [72,74,76,79,83,87]. As the adrenal 
cortex is of mesodermic origin, whereas the adrenal medulla is of ectodermic origin, these 
common changes in microRNA expression might even suggest some common adrenal-
specific features in tumorigenesis. Confirmation in larger cohorts is warranted.  
Based on these significant differences in expression profiles, miR, lncRNA, and 
circRNA profile analysis are still one of the chief candidates for an adjunct diagnostic 
marker for “hard-to-diagnose” tumors.  
3.4. ncRNAs as Therapeutic Targets in PPGL 
Currently, there are no clinical studies evaluating ncRNAs as therapeutic targets in 
PPGL. Since treatment options for metastatic PPGL are rather limited, novel molecular 
targets are intensively sought for. We can only hypothesize on the relevance of ncRNAs 
in the treatment of PPGL from specific observations. Some of the ncRNA detailed above 
i re 3. i i teracti s i e c r c t a: Tra s e ra e t r si e i ase rece t r acti ati is t e first ste
in the mTOR signaling pathway; thunderbolt represents activation of mTOR pathway in pheochromocytoma; P indicates
phosphorylation sites; blunt-head lines indicate inhibition; faded arrows indicate downstream activation; solid arrows
indicate direct activation; right-angle arrow indicates gene expression. Abbreviations: BSN-AS2: long non-coding RNA
BSN-AS2; OS: overall survival; PTPRJ: receptor-type tyrosine-protein phosphatase eta; TGFBR3: transforming growth
factor beta receptor 3; PI3K: phosphoinositide 3-kinase; PTEN: phosphatase and tensin homolog; PDK1: phosphoinositide-
dependent kinase 1; AKT1: a serine/threonine protein kinase; TSC1/2: tuberous sclerosis complex subunit 1; Rheb: Ras
homolog enriched in b in; GTP: guanosine triph sphate; GDP: gua osine diphosphate; mTROC1: mamm lian target of
rapamycin complex 1; rapamycin: mTOR inhibitor; UCA1: long non-coding RNA urothelial cancer associated 1; SOX6: SRY
(sex determining region Y)-box 6; HIF-1 α/β: hypoxia inducible factor 1 subunit α/β; HRE: hypoxia response element;
PC-12: pheochromocytoma 12 cell line, OS: overall survival. Note that miR-18 mediated down-regulation of HIF-1α has
only been established in lung cancer stem-like cells, choroidal endothelial cells, and in breast cancer xenograft model and
not yet in pheochromocytoma cells.
4. Conclusions
Pheochromocytoma was originally named after its microscopic and staining features
and due to the complex nature of the disease, current diagnostics encompasses not only
imaging and laboratory tests, but also the quest for new biomarkers on the horizon of an
ever-evolving field of non-protein-coding ribonucleic acids. The emerging role of non-
coding RNA in the setting of clinical evaluation and therapeutic approaches of clinically
challenging tumors is an attractive candidate for precision medicine. By studying non-
coding RNA, we might be able to double attack the therapeutic and the diagnostic ends of
PPGL in our efforts towards making a reliable tool for the distinction and targeted therapy
of metastatic and benign tumors.
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